DUBA antikoerper, AA407879 antikoerper, AI553596 antikoerper, BB114028 antikoerper, DXImx46e antikoerper, Sfc7 antikoerper, otud5 antikoerper, si:bz30i22.1 antikoerper, si:rp71-30i22.1 antikoerper, zgc:154072 antikoerper, wu:fi28a06 antikoerper, zgc:100839 antikoerper, OTU deubiquitinase 5 antikoerper, OTU domain containing 5 antikoerper, OTU deubiquitinase 5a antikoerper, OTU deubiquitinase 5 S homeolog antikoerper, OTU deubiquitinase 5 L homeolog antikoerper, OTU deubiquitinase 5b antikoerper, OTUD5 antikoerper, Otud5 antikoerper, otud5a antikoerper, otud5.S antikoerper, otud5.L antikoerper, otud5b antikoerper
Hintergrund
OTUD5 is a member of the OTU (ovarian tumor) domain-containing cysteine protease superfamily. The OTU domain confers deubiquitinase activity and OTUD5 has been shown to suppress the type I interferon (IFN-I)-dependent innate immune response by cleaving the polyubiquitin chain from TRAF3, an essential type I interferon adaptor protein. Cleavage results in disassociation of TRAF3 from a downstream signaling complex containing TBK1 and the disruption of the IFN-I signaling cascade, indicating that OTUD5 acts as a negative regulator of innate immune responses. It has been suggested that by suppressing IFN-I production, OTUD5 may function to inhibit the emergence of certain autoimmune disorders such as systemic lupus erythematosus. Multiple isoforms of OTUD5 are known to exist.Synonyms: DUBA, Deubiquitinating enzyme A, OTU domain-containing protein 5